A Novel Therapeutic Vaccine (EO2401) in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma (Spencer)

NCT04187404 PHASE1, PHASE2 TERMINATED Results posted

This is a multicenter, Phase 1/2, First-In-Human study to assess the safety, tolerability, immunogenicity, and preliminary efficacy of EO2401 in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma.

Details

Lead sponsor	Enterome
Phase	PHASE1, PHASE2
Status	TERMINATED
Enrolment	70
Start date	Thu Jul 23 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Wed Oct 02 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Adrenocortical Carcinoma
• Pheochromocytoma
• Paraganglioma

Interventions

• EO2401
• Nivolumab

Countries

Denmark, France, Italy, Netherlands, Sweden, Germany, United States, Spain